Emeryville, Calif. – November 29, 2017 – Berkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, announced today that Teva Pharmaceuticals Australia, Pty. Ltd. has implemented BLI’s Beacon platform in their antibody discovery programs.
The Beacon platform is capable of screening thousands of antibody producing cells in less than a day. Cell characterizations are performed through a variety of serial or multiplex fluorescence assays to determine antibody binding, affinity, and functional response. Individual cells with the desired characteristics are selected and exported for genomic profiling. All of these functions are automated and are performed with minimal hands on time by researchers.
“Technology, deep learning, and automation are driving rapid advances in biological processes to accelerate science forward,” said Eric Hobbs, PhD, CEO at BLI. “At Berkeley Lights, our mission is to marry engineering and biology in our Beacon platform to help automate manual lab workflows to speed discovery and the development of new therapeutics.”
About Berkeley Lights:
Berkeley Lights, Inc. (BLI) develops and commercializes platforms on which many bio-pharmaceutical, genomic, and cellular therapy applications will run. BLI launched its first commercial platform, the Beacon™*, in December 2016. The Beacon platform is ideally suited for cell line development and direct B-cell (plasma and memory cells) antibody discovery workflows. The flexibility of the Beacon platform allows users to automate biological processes and BLI is continuously developing new applications to align with its partners’ requirements. BLI’s technologies make it possible for customers to accelerate learning and dramatically improve workflows.
* For Research Use Only. Not for use in diagnostic procedures.